Clinical Trials on Advanced Non-squamous NSCLC in India

Total 24 results

Swami Rama Cancer Hospital and Research Institute

Unknown

Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma

Lung Cancer | Squamous Cell Carcinoma of the Lung | Locally Advanced and Metastatic Squamous Cell Carcinoma of the Lung

India
Daiichi Sankyo, Inc.

Completed

Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, India, Germany
AstraZeneca

Completed

Osimertinib Study in Indian Patients

Non Small Cell Lung Cancer (NSCLC)

India
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (PMS LAD SCCHN)

Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck | LA SCCHN

India
AstraZeneca

Completed

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced, NSCLC

Unresectable Non-small Cell Lung Cancer (NSCLC) and Urothelial Cancer

India
AstraZeneca

Completed

Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer). (CONCORDANCE)

NSCLC (Non-small Cell Lung Cancer)

India
Bristol-Myers Squibb

Completed

Study of Nivolumab for Advanced Cancers in India

Kidney Cancer | Kidney Neoplasms | Nonsmall Cell Lung Cancer | Renal Cancer | Non-Small-Cell Lung Carcinoma | Non-Small Cell Lung Cancer (NSCLC) | Renal Neoplasms

India
AstraZeneca

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

Locally Advanced Head and Neck Squamous Cell Carcinoma

Spain, United States, Italy, Korea, Republic of, United Kingdom, Vietnam, France, Japan, Brazil, India, Thailand, Germany, Canada, Turkey, Malaysia, Taiwan, Belgium, Austria, Hungary
Hoffmann-La Roche

Terminated

A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Korea, Republic of, Canada, Australia, Russian Federation, United Kingdom, Belgium, Brazil, China, France, Italy, Portugal, Spain, Japan, India, Thailand, Ukraine, Taiwan, Poland, Turkey, Hungary, South Africa, Germany
AstraZeneca

Completed

A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients (KINDLE)

Non-small-cell Lung Cancer (NSCLC)

Mexico, Peru, Argentina, Taiwan, India, Thailand, Colombia, Uruguay, Chile, Dominican Republic
Pfizer

Completed

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Advanced Non-Small Cell Lung Cancer

India
AstraZeneca

Approved for marketing

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Non Small Cell Lung Cancer (NSCLC)

Taiwan, Thailand, Turkey, Brazil, Philippines, Russian Federation, Romania, Austria, Hungary, Bulgaria, Latvia, India, Argentina, Australia, Estonia, Malaysia, Mexico, Singapore, South Africa
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Non-small Cell Lung Cancer (NSCLC)

Japan, Germany, Spain, Italy, France, Thailand, Belgium, Netherlands, India, Malaysia, Taiwan, Australia, Canada, Czechia, Greece, Hong Kong
Pfizer

Completed

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung (PROFILE 1014)

Non Squamous Lung Cancer

United States, Switzerland, Taiwan, Spain, Korea, Republic of, Canada, United Kingdom, Singapore, Japan, Germany, Luxembourg, Australia, France, Brazil, Italy, Hong Kong, China, Belgium, Russian Federation, Austria, Finland, Portugal and more
AstraZeneca

Active, not recruiting

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION)

Non-small Cell Lung Cancer NSCLC

United Kingdom, Belgium, United States, Korea, Republic of, Hungary, Japan, Russian Federation, Poland, Ukraine, India, Mexico, Netherlands
Novartis Pharmaceuticals

No longer available

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Non-small Cell Lung Cancer (NSCLC)

United States, Argentina, Korea, Republic of, Hong Kong, Thailand, Mexico, Jordan, Colombia, India, Philippines
Peregrine Pharmaceuticals

Completed

Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

United States, India, Georgia, Russian Federation, Ukraine
AstraZeneca

Active, not recruiting

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE)

Non Small Cell Lung Carcinoma NSCLC

Denmark, United Kingdom, United States, Poland, Brazil, India, Japan, Mexico, Peru, Russian Federation, Turkey, China, Malaysia, Hong Kong, Korea, Republic of, Chile, Israel, Ukraine, Portugal, Greece, Bulgaria, Philippines, Sweden, A... and more
AstraZeneca

Recruiting

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)

NSCLC

China, United States, United Kingdom, Korea, Republic of, Italy, Hungary, Spain, Vietnam, France, Brazil, Canada, Japan, Taiwan, Germany, Austria, Turkey, India, Peru, Poland, Sweden, Bulgaria, Greece, Mexico, Denmark
Aurigene Discovery Technologies Limited

Recruiting

A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies (JIVAN)

Kidney Cancer | Gastric Cancer | Non Small Cell Lung Cancer | Colon Cancer | Urothelial Carcinoma | Relapse | Esophagus Cancer | Advanced Malignant Neoplasm

India
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Italy, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom
AstraZeneca
Daiichi Sankyo

Recruiting

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China, Korea, Republic of, United States, Germany, Italy, Poland, Belgium, Mexico, Turkey, Spain, France, Canada, Taiwan, Brazil, Austria, Hong Kong, India, Japan, Netherlands, Denmark
AstraZeneca
Parexel

Recruiting

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)

Advanced or Metastatic Non-Small Cell Lung Cancer

China, Netherlands, Korea, Republic of, Italy, Spain, Canada, Hungary, Japan, Argentina, France, United States, Taiwan, Poland, Serbia, United Kingdom, Hong Kong, Brazil, Germany, Belgium, Romania, India, Ireland, Australia
Pfizer

Terminated

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

Carcinoma, Non-Small-Cell Lung | Carcinoma, Squamous Cell | Carcinoma, Adenosquamous | Carcinoma, Large Cell

United States, Bulgaria, Canada, Ukraine, Greece, Austria, France, Korea, Republic of, Poland, Russian Federation, Spain, Turkey, Finland, Hungary, Taiwan, Italy, Japan, Australia, Germany, Brazil, India, Puerto Rico, Czech Republic, ... and more

Clinical Trials on Advanced Non-squamous NSCLC in India

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations